Ivan Špıčka
Impact in
- Hematology top 0.05%
- Multiple Myeloma Research and Treatments
- Oncology top 0.5%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
Papers in
- Hematology 167
- Multiple Myeloma Research and Treatments 165
- Oncology 73
- Peptidase Inhibition and Analysis 39
- Cancer Treatment and Pharmacology 33
- Co-authors
- Antonio Pierangelo Palumbo (9 shared papers)Pieter Sonneveld (9 shared papers)Andrew G Spencer (8 shared papers)María‐Victoria Mateos (14 shared papers)Tamás Masszi (12 shared papers)Roman Hajek (48 shared papers)Meral Beksaç (7 shared papers)Katja Christina Weisel (6 shared papers)
- Journals
- Blood (36 papers)European Journal Of Haematology (10 papers)British Journal of Haematology (9 papers)Journal of Clinical Oncology (8 papers)Blood Cancer Journal (8 papers)
- Partner nations
- CzechiaUnited StatesSpain
In The Last Decade
Ivan Špıčka
165 papers receiving 11.8k citations
Ivan Špıčka's Hit Papers
Peers
Comparison fields: 5 of 106
- Hematology 10.0k
- Oncology 5.3k
- Genetics 1.1k
- Molecular Biology 6.6k
- Immunology 621
Countries citing papers authored by Ivan Špıčka
This map shows the geographic impact of Ivan Špıčka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Špıčka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Špıčka more than expected).
Fields of papers citing papers by Ivan Špıčka
This network shows the impact of papers produced by Ivan Špıčka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Špıčka. The network helps show where Ivan Špıčka may publish in the future.
Co-authors
The 25 scholars most cited alongside Ivan Špıčka, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 179 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma Hit paper breakdown → | 2008 | 1579 |
| 2 | Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma Hit paper breakdown → | 2016 | 1253 |
| 3 | Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Hit paper breakdown → | 2014 | 1125 |
| 4 | Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma Hit paper breakdown → | 2015 | 1112 |
| 5 | Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma Hit paper breakdown → | 2012 | 636 |
| 6 | Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression Hit paper breakdown → | 2007 | 556 |
| 7 | Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study Hit paper breakdown → | 2019 | 516 |
| 8 | 2010 | 376 | |
| 9 | Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial Hit paper breakdown → | 2021 | 288 |
| 10 | Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2020 | 252 |
| 11 | 2018 | 229 | |
| 12 | 2012 | 215 | |
| 13 | 2020 | 198 | |
| 14 | 2018 | 195 | |
| 15 | 2008 | 174 | |
| 16 | Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma Hit paper breakdown → | 2024 | 149 |
| 17 | 2010 | 119 | |
| 18 | 2017 | 119 | |
| 19 | 2014 | 117 | |
| 20 | 2020 | 117 |
About Ivan Špıčka
Ivan Špıčka is a scholar working on Hematology, Oncology, Molecular Biology, Genetics and Pathology and Forensic Medicine, having authored 179 papers that have together received 12.1k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (165 papers), Protein Degradation and Inhibitors (53 papers), Peptidase Inhibition and Analysis (39 papers), Cancer Treatment and Pharmacology (33 papers), Cancer therapeutics and mechanisms (14 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (10 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). The work is most often cited by research in Hematology (10.0k citations), Oncology (5.3k citations), Genetics (1.1k citations), Molecular Biology (6.6k citations) and Immunology (621 citations). Ivan Špıčka has collaborated with scholars based in Czechia, United States and Spain. Frequent co-authors include Antonio Pierangelo Palumbo, Pieter Sonneveld, Andrew G Spencer, María‐Victoria Mateos, Tamás Masszi, Roman Hajek, Meral Beksaç, Katja Christina Weisel, William M Deraedt and Tomer Martin Mark. Their work appears in journals such as Blood, European Journal Of Haematology, British Journal of Haematology, Journal of Clinical Oncology and Blood Cancer Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.